JNJ

JOHNSON & JOHNSON

HealthcareCIK 0000200406

Loading...

Market Cap
$578.94B
P/E (TTM)
27.5x
Rev Growth (TTM)
+7.9%
Net Margin (TTM)
21.8%
FCF Yield (TTM)
3.1%
FCF Margin (TTM)
18.5%

Filings your agent reads

Factsheet

Primary-source SEC disclosures, read end-to-end — every figure traceable to its filing.

Point your agent at JNJ and it navigates these the same way — citing each number back to the filing.

LATEST EARNINGS

Q1 2026
3 months ago
View source
Revenue
$24.06B
+9.9%
Net Income
$5.24B
-52.4%
EPS
$2.14
-52.9%
Gross
66.3% -0.1%
Operating
24.9% -37.4%
Net
21.8% -28.4%
  • Worldwide sales increased 9.9% to $24.1 billion, driven by strong performance in both Innovative Medicine and MedTech segments.
  • Innovative Medicine segment sales grew 11.2% operationally to $15.4 billion, with strong contributions from Oncology and Neuroscience.
  • MedTech segment sales increased 7.7% operationally to $8.6 billion, with growth across Cardiovascular, Surgery, Vision, and Orthopaedics.
  • Operational sales growth of 6.4% globally, indicating strong underlying business performance.

Cash Flow Health

Free Cash Flow8/8 positive
TTM$17.8B
Q1 '27
$1.5B-73%
Q4 '26
$5.5B-32%
FCF Margin
TTM18.5%
Q1 '276.1%-73%
Sector: 0.0%Top 10%
OCF Margin23.7%
OCF/NI1.09x
CapEx Coverage4.5x
FCF Yield3.1%
FCF Growth (2Y)+3%
Cash Conversion Cycle
108 days
DSO: 66+DIO: 163DPO: 121

Capital Allocation & Returns

Balanced
Total Shareholder YieldTTM
TTM3.5%
Div Yield2.2%
+
Buyback (TTM)1.4%

Balancing returns with reinvestment

Dividend & Payout Metrics
Dividend Yield (TTM)2.2%
FCF Payout Ratio70.4%
Free Cash Flow (TTM)$17.8B
Stock Repurchases (TTM)$7.9B
Capital Return / FCF114.6%
Est. Dividends Paid (TTM)$12.5B
Shows how management rewards shareholders

Operational Efficiency & Returns

Return on Invested CapitalTTM
16.8%
Stable
+0.0% YoY+0.7%
P25MedianP75
75th pctl (med: -0.0%)
DuPont BreakdownROIC = Margin × Turn × (1+D/E)
NOPAT Margin
22.6%
8Q: 23.0%
Asset Turnover
0.49x
8Q: 0.50x
Leverage (1+D/E)
1.68x
D/E: 0.68x
DuPont: 18.7%16.8% ROIC
Asset & CapEx Efficiency
Fixed Asset Turn
4.31x
8Q:4.36x
-30.3%
Invested Cap Turn
0.79x
8Q:0.80x
-8.4%
CapEx Intensity
4.2%
8Q:3.8%
CapEx/Depreciation
0.66x
Asset-based ROIC formula

Valuation Analysis

Fair Value
Price-to-EarningsTTM
27.5x
Volatile
8Q: 90.8x-32%
High PEG ratio (3.5x) suggests expensive for growth
Valuation Lenses
Earnings
27.5x
vs sector
Cash Flow
34.1x
EV/FCF vs
Growth-Adj
3.5xPEG
Expensive for growth
Quality-Adj
1.6P/E per %ROIC
ROIC: 16.8%
Shareholder Returns
Dividend
2.2%
Buyback
1.4%
Total Yield
3.5%
Market Cap$578.94B
EV$606.48B
Multi-angle valuation analysis with sector context

Business Quality & Moat

Overall Quality Score
97/100
Exceptional

Composite score: Returns (40%) + Consistency (30%) + Earnings Quality (30%)

Returns on Capital

Return on Equity (ROE)Top 25%
26.4%
8Q:
Return on Invested Capital (ROIC)Top 25%
16.8%
8Q:
Flat
vs Sector:-0.0%

DuPont Analysis (ROIC = NOPAT Margin × Asset Turnover)

NOPAT Margin: 22.6%
Asset Turnover: 0.49x

Earnings Quality

Cash Conversion

1.09x

OCF / Net Income

FCF Consistency

Positive quarters

Competitive Moat Indicators

Pricing Power

Gross Margin67.8%

Capital Efficiency

Invested Capital Turnover0.79x

Working Capital

Cash Conversion Cycle108 days

Growth Quality & Momentum

Moderate Growth
Growth Quality Score
59/100
Growth 40%
Margins 30%
FCF 20%
Consistency 10%

Growth Rates

Revenue Growth YoY
7.9%
OpInc Growth YoY
3.2%
EPS Growth YoY
-3.9%
FCF 3Y CAGR
3.1%

Margin Quality & Sustainability

Moderate
Profitability Cascade
Gross
67.8%
Operating
26.8%
Top 25% in sector
Net
21.8%
Margins Unknown
Earnings Quality Signals
SBC / Revenue
FCF vs Net Gap
-3.4 pts
FCF: 18.5% | Net: 21.8%

Quality = stability + cash conversion + low dilution

Balance Sheet & Solvency

Adequate
Net Debt / EBITDA
Net Debt: $32.94B
Interest Coverage
Leverage Metrics
Debt-to-Equity
0.68x
Balance sheet risk & solvency analysis